18 June 2013
Keywords: roche, actemra, inhibits, ra, joint, damage, boost
Article | 19 May 2008
Late-stage trial data show that Roche's Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with
rheumatoid arthritis, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 May 2008
5 May 2008
© 2013 thepharmaletter.com